STOCK TITAN

[Form 4] Klaviyo, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Atlas Venture funds have filed Amendment No. 1 to their Schedule 13D for ImageneBio, Inc. (formerly Ikena Oncology, Nasdaq: IKNA) to report dilution of their holdings after the 1-for-12 reverse stock split and completion of Ikena’s all-stock merger with Inmagene on 25 Jul 2025.

  • Collectively, the reporting entities now own 418,179 post-split common shares, equal to 3.6 % of the 11.6 million shares outstanding.
  • Breakdown: Fund X 241,800 shares (2.1 %), Fund XI 103,494 shares (0.9 %), Opportunity Fund I 72,885 shares (0.6 %).
  • All voting and dispositive powers are shared among the respective limited partnerships and their general partners; no sole voting power is reported.
  • The funds ceased to be 5 % beneficial owners on 25 Jul 2025; no purchases or sales occurred in the past 60 days.
  • Purpose: administrative update reflecting dilution from the merger and reverse split; Atlas Venture continues to hold the same absolute number of economic shares pre-transaction but a lower percentage.

Atlas Venture disclaims group status among the reporting persons. A joint filing agreement is included as Exhibit 99.1.

I fondi Atlas Venture hanno presentato l'Emendamento n. 1 al loro Schedule 13D per ImageneBio, Inc. (precedentemente Ikena Oncology, Nasdaq: IKNA) per segnalare la diluizione delle loro partecipazioni dopo lo split azionario inverso 1-per-12 e il completamento della fusione interamente azionaria di Ikena con Inmagene il 25 luglio 2025.

  • Collettivamente, gli enti segnalanti detengono ora 418.179 azioni ordinarie post-split, pari al 3,6% delle 11,6 milioni di azioni in circolazione.
  • Dettaglio: Fund X 241.800 azioni (2,1%), Fund XI 103.494 azioni (0,9%), Opportunity Fund I 72.885 azioni (0,6%).
  • Tutti i poteri di voto e dispositivi sono condivisi tra le rispettive società in accomandita semplice e i loro soci accomandatari; non è riportato alcun potere di voto esclusivo.
  • I fondi hanno cessato di essere beneficiari del 5% il 25 luglio 2025; non si sono verificati acquisti o vendite negli ultimi 60 giorni.
  • Scopo: aggiornamento amministrativo per riflettere la diluizione derivante dalla fusione e dallo split inverso; Atlas Venture continua a detenere lo stesso numero assoluto di azioni economiche pre-transazione ma con una percentuale inferiore.

Atlas Venture nega lo status di gruppo tra le persone segnalanti. Un accordo di deposito congiunto è incluso come Allegato 99.1.

Los fondos Atlas Venture han presentado la Enmienda No. 1 a su Schedule 13D para ImageneBio, Inc. (anteriormente Ikena Oncology, Nasdaq: IKNA) para reportar la dilución de sus participaciones tras la división inversa de acciones 1 por 12 y la finalización de la fusión totalmente en acciones de Ikena con Inmagene el 25 de julio de 2025.

  • En conjunto, las entidades informantes ahora poseen 418,179 acciones comunes posteriores a la división, equivalentes al 3.6% de las 11.6 millones de acciones en circulación.
  • Desglose: Fund X 241,800 acciones (2.1%), Fund XI 103,494 acciones (0.9%), Opportunity Fund I 72,885 acciones (0.6%).
  • Todos los poderes de voto y disposición se comparten entre las sociedades limitadas respectivas y sus socios generales; no se reporta ningún poder de voto exclusivo.
  • Los fondos dejaron de ser propietarios beneficiarios del 5% el 25 de julio de 2025; no hubo compras ni ventas en los últimos 60 días.
  • Propósito: actualización administrativa para reflejar la dilución derivada de la fusión y la división inversa; Atlas Venture continúa manteniendo el mismo número absoluto de acciones económicas previas a la transacción pero con un porcentaje menor.

Atlas Venture niega el estatus de grupo entre las personas que informan. Se incluye un acuerdo de presentación conjunta como Anexo 99.1.

Atlas Venture 펀드들은 ImageneBio, Inc. (이전 명칭 Ikena Oncology, Nasdaq: IKNA)에 대한 Schedule 13D의 수정안 1호를 제출하여 2025년 7월 25일 Ikena와 Inmagene 간의 전액 주식 합병 완료 및 1대 12 역주식 분할 이후 보유 지분 희석을 보고했습니다.

  • 보고 기관들은 현재 합산하여 418,179 주의 역분할 후 보통주를 보유하고 있으며, 이는 총 1,160만 주 중 3.6%에 해당합니다.
  • 내역: Fund X 241,800 주 (2.1%), Fund XI 103,494 주 (0.9%), Opportunity Fund I 72,885 주 (0.6%).
  • 모든 의결권 및 처분권은 각 유한책임조합과 그 일반 파트너 간에 공유되며, 단독 의결권은 보고되지 않았습니다.
  • 펀드들은 2025년 7월 25일부로 5% 이상 소유주 자격을 상실했으며, 지난 60일간 매매는 없었습니다.
  • 목적: 합병 및 역주식 분할로 인한 희석 반영을 위한 행정적 업데이트; Atlas Venture는 거래 전과 동일한 절대 수의 경제적 주식을 보유하지만 비율은 낮아졌습니다.

Atlas Venture는 보고자들 간에 그룹 지위를 부인합니다. 공동 제출 계약서는 부속서 99.1로 포함되어 있습니다.

Les fonds Atlas Venture ont déposé l'Amendement n°1 à leur Schedule 13D pour ImageneBio, Inc. (anciennement Ikena Oncology, Nasdaq : IKNA) afin de signaler la dilution de leurs participations après la division inversée d'actions 1 pour 12 et l'achèvement de la fusion entièrement en actions d'Ikena avec Inmagene le 25 juillet 2025.

  • Collectivement, les entités déclarantes détiennent désormais 418 179 actions ordinaires post-division, soit 3,6 % des 11,6 millions d'actions en circulation.
  • Répartition : Fund X 241 800 actions (2,1 %), Fund XI 103 494 actions (0,9 %), Opportunity Fund I 72 885 actions (0,6 %).
  • Tous les pouvoirs de vote et de disposition sont partagés entre les sociétés en commandite respectives et leurs associés commandités ; aucun pouvoir de vote exclusif n'est déclaré.
  • Les fonds ont cessé d'être des propriétaires bénéficiaires à hauteur de 5 % le 25 juillet 2025 ; aucun achat ni vente n'a eu lieu au cours des 60 derniers jours.
  • Objectif : mise à jour administrative reflétant la dilution résultant de la fusion et de la division inversée ; Atlas Venture continue de détenir le même nombre absolu d'actions économiques avant la transaction, mais un pourcentage inférieur.

Atlas Venture décline le statut de groupe parmi les personnes déclarantes. Un accord de dépôt conjoint est inclus en Annexe 99.1.

Die Atlas Venture Fonds haben Änderungsmitteilung Nr. 1 zu ihrem Schedule 13D für ImageneBio, Inc. (ehemals Ikena Oncology, Nasdaq: IKNA) eingereicht, um die Verwässerung ihrer Beteiligungen nach dem 1-zu-12 Reverse Stock Split und dem Abschluss der vollständigen Aktientauschfusion von Ikena mit Inmagene am 25. Juli 2025 zu melden.

  • Gemeinsam halten die meldenden Stellen nun 418.179 nach dem Split ausgegebene Stammaktien, was 3,6% von 11,6 Millionen ausstehenden Aktien entspricht.
  • Aufschlüsselung: Fund X 241.800 Aktien (2,1 %), Fund XI 103.494 Aktien (0,9 %), Opportunity Fund I 72.885 Aktien (0,6 %).
  • Alle Stimm- und Verfügungsrechte werden unter den jeweiligen Kommanditgesellschaften und deren Komplementären geteilt; kein alleiniges Stimmrecht wird gemeldet.
  • Die Fonds haben am 25. Juli 2025 den Status als 5%-Eigentümer verloren; in den letzten 60 Tagen gab es keine Käufe oder Verkäufe.
  • Zweck: administrative Aktualisierung zur Berücksichtigung der Verwässerung durch die Fusion und den Reverse Split; Atlas Venture hält weiterhin die gleiche absolute Anzahl wirtschaftlicher Aktien vor der Transaktion, jedoch einen geringeren Prozentsatz.

Atlas Venture weist den Gruppenstatus unter den meldenden Personen zurück. Eine gemeinsame Einreichungsvereinbarung ist als Anlage 99.1 beigefügt.

Positive
  • No insider selling: Atlas Venture did not dispose of any shares, signalling continued support for ImageneBio.
  • Merger completion and reverse split finalized, providing corporate clarity after the Inmagene transaction.
Negative
  • Ownership dilution: Atlas Venture’s combined stake falls below 5 %, slightly reducing insider alignment.
  • Lower reporting threshold: Future 13D filings may cease unless ownership rises again, reducing visibility into a key holder’s changes.

Insights

TL;DR – Atlas Venture’s stake falls to 3.6 % due to merger-related dilution; no shares sold, impact on IKNA share supply already known.

The amendment is largely administrative. Atlas Venture’s absolute share count is unchanged, but the completed Inmagene merger and 1-for-12 reverse split expanded the denominator, cutting their ownership below the 5 % 13D threshold. The filing removes a potential overhang concern of insider selling, as none occurred. From a governance lens, the reduced concentration slightly broadens the float, but Atlas remains a meaningful holder. Market impact is likely minimal because the share count change was disclosed in the July 25 reverse-split announcement and already reflected in trading. Overall, neutral for valuation and liquidity.

I fondi Atlas Venture hanno presentato l'Emendamento n. 1 al loro Schedule 13D per ImageneBio, Inc. (precedentemente Ikena Oncology, Nasdaq: IKNA) per segnalare la diluizione delle loro partecipazioni dopo lo split azionario inverso 1-per-12 e il completamento della fusione interamente azionaria di Ikena con Inmagene il 25 luglio 2025.

  • Collettivamente, gli enti segnalanti detengono ora 418.179 azioni ordinarie post-split, pari al 3,6% delle 11,6 milioni di azioni in circolazione.
  • Dettaglio: Fund X 241.800 azioni (2,1%), Fund XI 103.494 azioni (0,9%), Opportunity Fund I 72.885 azioni (0,6%).
  • Tutti i poteri di voto e dispositivi sono condivisi tra le rispettive società in accomandita semplice e i loro soci accomandatari; non è riportato alcun potere di voto esclusivo.
  • I fondi hanno cessato di essere beneficiari del 5% il 25 luglio 2025; non si sono verificati acquisti o vendite negli ultimi 60 giorni.
  • Scopo: aggiornamento amministrativo per riflettere la diluizione derivante dalla fusione e dallo split inverso; Atlas Venture continua a detenere lo stesso numero assoluto di azioni economiche pre-transazione ma con una percentuale inferiore.

Atlas Venture nega lo status di gruppo tra le persone segnalanti. Un accordo di deposito congiunto è incluso come Allegato 99.1.

Los fondos Atlas Venture han presentado la Enmienda No. 1 a su Schedule 13D para ImageneBio, Inc. (anteriormente Ikena Oncology, Nasdaq: IKNA) para reportar la dilución de sus participaciones tras la división inversa de acciones 1 por 12 y la finalización de la fusión totalmente en acciones de Ikena con Inmagene el 25 de julio de 2025.

  • En conjunto, las entidades informantes ahora poseen 418,179 acciones comunes posteriores a la división, equivalentes al 3.6% de las 11.6 millones de acciones en circulación.
  • Desglose: Fund X 241,800 acciones (2.1%), Fund XI 103,494 acciones (0.9%), Opportunity Fund I 72,885 acciones (0.6%).
  • Todos los poderes de voto y disposición se comparten entre las sociedades limitadas respectivas y sus socios generales; no se reporta ningún poder de voto exclusivo.
  • Los fondos dejaron de ser propietarios beneficiarios del 5% el 25 de julio de 2025; no hubo compras ni ventas en los últimos 60 días.
  • Propósito: actualización administrativa para reflejar la dilución derivada de la fusión y la división inversa; Atlas Venture continúa manteniendo el mismo número absoluto de acciones económicas previas a la transacción pero con un porcentaje menor.

Atlas Venture niega el estatus de grupo entre las personas que informan. Se incluye un acuerdo de presentación conjunta como Anexo 99.1.

Atlas Venture 펀드들은 ImageneBio, Inc. (이전 명칭 Ikena Oncology, Nasdaq: IKNA)에 대한 Schedule 13D의 수정안 1호를 제출하여 2025년 7월 25일 Ikena와 Inmagene 간의 전액 주식 합병 완료 및 1대 12 역주식 분할 이후 보유 지분 희석을 보고했습니다.

  • 보고 기관들은 현재 합산하여 418,179 주의 역분할 후 보통주를 보유하고 있으며, 이는 총 1,160만 주 중 3.6%에 해당합니다.
  • 내역: Fund X 241,800 주 (2.1%), Fund XI 103,494 주 (0.9%), Opportunity Fund I 72,885 주 (0.6%).
  • 모든 의결권 및 처분권은 각 유한책임조합과 그 일반 파트너 간에 공유되며, 단독 의결권은 보고되지 않았습니다.
  • 펀드들은 2025년 7월 25일부로 5% 이상 소유주 자격을 상실했으며, 지난 60일간 매매는 없었습니다.
  • 목적: 합병 및 역주식 분할로 인한 희석 반영을 위한 행정적 업데이트; Atlas Venture는 거래 전과 동일한 절대 수의 경제적 주식을 보유하지만 비율은 낮아졌습니다.

Atlas Venture는 보고자들 간에 그룹 지위를 부인합니다. 공동 제출 계약서는 부속서 99.1로 포함되어 있습니다.

Les fonds Atlas Venture ont déposé l'Amendement n°1 à leur Schedule 13D pour ImageneBio, Inc. (anciennement Ikena Oncology, Nasdaq : IKNA) afin de signaler la dilution de leurs participations après la division inversée d'actions 1 pour 12 et l'achèvement de la fusion entièrement en actions d'Ikena avec Inmagene le 25 juillet 2025.

  • Collectivement, les entités déclarantes détiennent désormais 418 179 actions ordinaires post-division, soit 3,6 % des 11,6 millions d'actions en circulation.
  • Répartition : Fund X 241 800 actions (2,1 %), Fund XI 103 494 actions (0,9 %), Opportunity Fund I 72 885 actions (0,6 %).
  • Tous les pouvoirs de vote et de disposition sont partagés entre les sociétés en commandite respectives et leurs associés commandités ; aucun pouvoir de vote exclusif n'est déclaré.
  • Les fonds ont cessé d'être des propriétaires bénéficiaires à hauteur de 5 % le 25 juillet 2025 ; aucun achat ni vente n'a eu lieu au cours des 60 derniers jours.
  • Objectif : mise à jour administrative reflétant la dilution résultant de la fusion et de la division inversée ; Atlas Venture continue de détenir le même nombre absolu d'actions économiques avant la transaction, mais un pourcentage inférieur.

Atlas Venture décline le statut de groupe parmi les personnes déclarantes. Un accord de dépôt conjoint est inclus en Annexe 99.1.

Die Atlas Venture Fonds haben Änderungsmitteilung Nr. 1 zu ihrem Schedule 13D für ImageneBio, Inc. (ehemals Ikena Oncology, Nasdaq: IKNA) eingereicht, um die Verwässerung ihrer Beteiligungen nach dem 1-zu-12 Reverse Stock Split und dem Abschluss der vollständigen Aktientauschfusion von Ikena mit Inmagene am 25. Juli 2025 zu melden.

  • Gemeinsam halten die meldenden Stellen nun 418.179 nach dem Split ausgegebene Stammaktien, was 3,6% von 11,6 Millionen ausstehenden Aktien entspricht.
  • Aufschlüsselung: Fund X 241.800 Aktien (2,1 %), Fund XI 103.494 Aktien (0,9 %), Opportunity Fund I 72.885 Aktien (0,6 %).
  • Alle Stimm- und Verfügungsrechte werden unter den jeweiligen Kommanditgesellschaften und deren Komplementären geteilt; kein alleiniges Stimmrecht wird gemeldet.
  • Die Fonds haben am 25. Juli 2025 den Status als 5%-Eigentümer verloren; in den letzten 60 Tagen gab es keine Käufe oder Verkäufe.
  • Zweck: administrative Aktualisierung zur Berücksichtigung der Verwässerung durch die Fusion und den Reverse Split; Atlas Venture hält weiterhin die gleiche absolute Anzahl wirtschaftlicher Aktien vor der Transaktion, jedoch einen geringeren Prozentsatz.

Atlas Venture weist den Gruppenstatus unter den meldenden Personen zurück. Eine gemeinsame Einreichungsvereinbarung ist als Anlage 99.1 beigefügt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Shopify Strategic Holdings 3 LLC

(Last) (First) (Middle)
103 FOULK ROAD, SUITE 218-A

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Klaviyo, Inc. [ KVYO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants to Purchase Series B Common Stock (Right to Buy) $0.01 07/28/2025 X 344,383 (1) 07/28/2032 Series B Common Stock 344,383 $0 2,755,057 D(2)
Series B Common Stock (3) 07/28/2025 X 344,383 (3) (3) Series A Common Stock 344,383 $0.01 15,939,963 D(2)
1. Name and Address of Reporting Person*
Shopify Strategic Holdings 3 LLC

(Last) (First) (Middle)
103 FOULK ROAD, SUITE 218-A

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SHOPIFY INC.

(Last) (First) (Middle)
151 O'CONNOR STREET
GROUND FLOOR

(Street)
OTTAWA A6 K2P 2L8

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. 25% of the shares subject to the warrants vested on July 28, 2022, and the remaining shares vest quarterly in equal amounts through July 28, 2027. Notwithstanding the foregoing, in connection with the Issuer's initial public offering ("IPO"), 25% of the total number of shares subject to the warrants vested immediately prior to the completion of the IPO.
2. Reflects securities held directly by Shopify Strategic Holdings 3 LLC, a wholly-owned subsidiary of Shopify Inc. ("Shopify"). Shopify is an indirect beneficial owner and disclaims beneficial ownership except to the extent of its pecuniary interest therein.
3. Each share of Series B Common Stock is convertible at any time at the option of the holder into one share of Series A Common Stock of the Issuer, and will automatically convert into Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date.
SHOPIFY STRATEGIC HOLDINGS 3 LLC, By: /s/ Jason Kilpela, Director 07/29/2025
SHOPIFY INC, By: /s/ Michael L. Johnson, Corporate Secretary 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Atlas Venture file an amended Schedule 13D for IKNA?

To report that its percentage ownership fell to 3.6 % after IKNA’s merger with Inmagene and a 1-for-12 reverse split on 25 Jul 2025.

How many IKNA shares does Atlas Venture now own?

Collectively 418,179 shares: Fund X 241,800; Fund XI 103,494; Opportunity Fund I 72,885.

Did Atlas Venture sell any IKNA shares?

No. The filing states no purchases or sales occurred in the past 60 days; dilution alone lowered the percentage.

What is IKNA’s new share count after the merger?

The filing references approximately 11.6 million common shares outstanding as of 25 Jul 2025.

Does Atlas Venture still have voting control over its IKNA shares?

Yes. Each fund and its general partners retain shared voting and dispositive power over their respective shares.
Klaviyo, Inc.

NYSE:KVYO

KVYO Rankings

KVYO Latest News

KVYO Latest SEC Filings

KVYO Stock Data

9.40B
63.33M
1%
83.74%
1.78%
Software - Infrastructure
Services-prepackaged Software
Link
United States
BOSTON